Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib and Benmelstobart in R/R ENKTL
NCT06733051Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golidocitinib and benmelstobart in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2024; status: recruiting.
02
Drugs
golidocitinibbenmelstobart
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06733051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733051.